Gaps in US Psychedelic Policy and How to Close Them
JAMA Health Forum November 7, 2025 Caleigh Propes, Katherine Cheung, Matthew D. Eisenberg et al. 4 citations
This viewpoint outlines strategies for addressing policy gaps that would arise if the US Food and Drug Administration approves psychedelics for treating mental health and substance use conditions. It discusses regulatory, clinical, and public health considerations necessary to integrate these therapies into practice.